Investing in cardiovascular research benefits economy

Main Category: Cardiovascular / Cardiology
Also Included In: Public Health
Article Date: 30 Jul 2013 - 2:00 PDT Current ratings for:
Investing in cardiovascular research benefits economy

Investing in cardiovascular disease research in Canada provides economic and societal benefits to Canadians, according to new research published in CMAJ Open.

"Our main goal was to understand how much "bang" we were getting from our research "buck" and whether investing in cardiovascular disease research is worthwhile from a population health perspective," writes Dr. Claire de Oliveira, scientist and health economist with the Centre for Addiction and Mental Health (CAMH), Toronto, with coauthors.

Cardiovascular disease is the number one cause of hospitalization and death in Canada. For every $69 spent on cardiovascular health care in the country, $1 was spent on research through public and charitable sector funding.

"We found an internal rate of return of 20.6% for investment in cardiovascular disease research by the public and charitable sectors," the authors write. "Thus, for every $1 spent on public or charitable sources, Canadians receive an income stream of about $0.21 per year in perpetuity. Considering a minimum acceptable rate of return of 12%, this investment is quite attractive."

The internal rate of return is "the annual monetary benefit to the economy for each dollar invested in cardiovascular disease research."

Spending on cardiovascular disease research in Canada has increased from roughly $13 million in 1975 to $41 million in 1990 and $96 million in 2005.

The authors hope this study will help funders determine the return on investment and whether they are spending appropriately.

"Our estimates provide evidence that investing in cardiovascular disease research is valuable and that investments in medical research are returned many times over in societal benefits," conclude the authors.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our cardiovascular / cardiology section for the latest news on this subject.

Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis

CMAJ Open - doi: 10.9778/cmajo.20130003

Authors: Claire de Oliveira, MA, PhD, Hai V. Nguyen, PhD, Harindra C. Wijeysundera, MD, PhD, William W.L. Wong, PhD, Gloria Woo, PhD, Paul Grootendorst, PhD, Peter P. Liu, MD, MSc, Murray D. Krahn, MD, MSc

CMAJ Open

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Open, CMAJ. "Investing in cardiovascular research benefits economy." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Investing in cardiovascular research benefits economy'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here

Cardiovascular R&D Revival Needed To Halt Growing CVD Epidemic

Main Category: Heart Disease
Also Included In: Public Health
Article Date: 11 Jul 2013 - 1:00 PDT Current ratings for:
Cardiovascular R&D Revival Needed To Halt Growing CVD Epidemic

A resurgence in cardiovascular R&D is urgently needed to curb a new epidemic of cardiovascular diseases, according to leading cardiologists and industry representatives in the Cardiovascular Round Table (CRT).

The CRT is an independent forum established by the European Society of Cardiology (ESC) and comprised of cardiologists and representatives of the pharmaceutical and medical device industries. The group's views are outlined in "Championing Cardiovascular Health Innovation in Europe", published in European Heart Journal (1).

Professor Michel Komajda (Pitié Salpetriere Hospital, Paris), past-president of the ESC and lead author of the paper, said: "Research and development in pharmacology for the management of cardiovascular diseases has been extremely powerful and efficient in Europe so far. The 30 day mortality after myocardial infarction has been more than halved in 20 years thanks to the new anti-thrombotic agents. The European economy has also benefited from the creation of high and middle profile jobs."

However, "we are worried that the period of improvement in treatment is reaching a limit," he added. The population is aging and there is an increase in comorbidities such as diabetes and obesity which induce cardiovascular diseases. At the same time research and development in CVD pharmacology is slowing down."

CVD is the leading cause of death in Europe but has not occupied a place in the top 5 active research areas since 2005. The CRT paper outlines how, compared with other medical areas, CVD related R&D is in steep decline. The authors state: "This is mostly due to the impact of complex regulation which drives up development costs and delays time-to-market for new cardiovascular drugs."

They add: "The recent closure of mainstream R&D facilities in Europe is clear evidence of an investment crisis that has to be addressed and a regulatory environment that must be simplified without compromising patients' safety which is our utmost duty."

Research and development has moved to other geographic regions and medical areas that are likely to yield better returns. There is a risk that cardiologists will not have access to the optimum treatment techniques at a time when a new CVD epidemic is gaining ground in Europe.

The authors recommend that a forum be established to discuss how to rejuvenate cardiovascular R&D in Europe. It should consist of EU representatives, national healthcare authorities and finance ministries, academia, medical societies and representatives of the pharmaceutical and medical device industries.

Their agenda should include:

Reviewing the issues driving R&D investment to other geographical and medical areas Simplifying the clinical trials environment Targeting EU funding through tax incentives and sponsored development programmes Reviewing patent duration in the context of development timescales and investment Encouraging cross-border and cross-discipline collaboration and networking.

Prof Komajda said: "As a professional society, the ESC believes it is our task to highlight how declining cardiovascular innovation threatens the availability of new treatments in Europe, a situation which leaves European citizens short of needed innovations and risks damaging the economy. We set up the CRT to increase awareness of these issues and kick start solutions."

He concludes: "A new epidemic of cardiovascular diseases is taking hold in Europe. Urgent steps are needed to halt this epidemic by removing the barriers to cardiovascular R&D in Europe."

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our heart disease section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

European Society of Cardiology. "Cardiovascular R&D Revival Needed To Halt Growing CVD Epidemic." Medical News Today. MediLexicon, Intl., 11 Jul. 2013. Web.
11 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.

'Cardiovascular R&D Revival Needed To Halt Growing CVD Epidemic'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

View the original article here